Literature DB >> 21228755

Targeting viral reservoirs: ability of antiretroviral therapy to stop viral replication.

Frank Maldarelli1.   

Abstract

PURPOSE OF REVIEW: HIV infection is controlled but not cured by combination antiretroviral therapy. HIV may persist for a number of reasons, including ongoing cycles of HIV infection or viral persistence as latent, or HIV replication in long-lived cells containing HIV proviruses. Therapeutic consequences of these alternative mechanisms are significant and distinct. If ongoing replication remains during current antiretroviral therapy, then improvements in potency will be useful in eradication strategies. Alternatively, long-lived cells with integrated proviruses will not be affected by improvements in therapy directed against active infection, and new strategies will be necessary for HIV eradication. Technologic advances have made it possible to carry out a series of drug intensification protocols in well suppressed patients; these and other analyses for HIV replication have been useful to elucidate the nature of HIV persistence on therapy. RECENT
FINDINGS: A number of clinical studies intensifying antiretroviral therapy carried out in the last several years have yielded new findings regarding the ability to detect the presence of ongoing replication. Decreases in persistent viremia have not been consistently detected in individuals on potent combination antiretroviral therapy. Evidence for persistent replication has been reported in patients using sensitive assays of cell-associated HIV.
SUMMARY: HIV viremia persists despite combination antiretroviral therapy. Antiretroviral drug intensification does not lower the level of HIV measured in plasma, suggesting current therapy arrests active virus replication. HIV eradication will most likely require therapy in addition to potent antiretroviral therapy.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21228755      PMCID: PMC7380717          DOI: 10.1097/COH.0b013e32834134ea

Source DB:  PubMed          Journal:  Curr Opin HIV AIDS        ISSN: 1746-630X            Impact factor:   4.283


  62 in total

1.  Quantification of integrated and total HIV-1 DNA after long-term highly active antiretroviral therapy in HIV-1-infected patients.

Authors:  A Ibáñez; T Puig; J Elias; B Clotet; L Ruiz; M A Martínez
Journal:  AIDS       Date:  1999-06-18       Impact factor: 4.177

2.  Measuring covert HIV replication during HAART: the abundance of 2-LTR circles is not a reliable marker.

Authors:  Frederic Bushman
Journal:  AIDS       Date:  2003-03-28       Impact factor: 4.177

3.  Role of macrophages in HIV infection and persistence.

Authors:  Stephanie Venzke; Oliver T Keppler
Journal:  Expert Rev Clin Immunol       Date:  2006-07       Impact factor: 4.473

4.  Decay of human immunodeficiency virus type 1 unintegrated DNA containing two long terminal repeats in infected individuals after 3 to 8 years of sustained control of viremia.

Authors:  Jennifer L McDermott; Isabella Martini; Davide Ferrari; Francesca Bertolotti; Claudio Giacomazzi; Giuseppe Murdaca; Francesco Puppo; Francesco Indiveri; Oliviero E Varnier
Journal:  J Clin Microbiol       Date:  2005-10       Impact factor: 5.948

5.  Human immunodeficiency virus cDNA metabolism: notable stability of two-long terminal repeat circles.

Authors:  Scott L Butler; Erik P Johnson; Frederic D Bushman
Journal:  J Virol       Date:  2002-04       Impact factor: 5.103

6.  Treatment intensification has no effect on the HIV-1 central nervous system infection in patients on suppressive antiretroviral therapy.

Authors:  Aylin Yilmaz; Chris Verhofstede; Antonio D'Avolio; Victoria Watson; Lars Hagberg; Dietmar Fuchs; Bo Svennerholm; Magnus Gisslén
Journal:  J Acquir Immune Defic Syndr       Date:  2010-12-15       Impact factor: 3.731

7.  Short-course raltegravir intensification does not reduce persistent low-level viremia in patients with HIV-1 suppression during receipt of combination antiretroviral therapy.

Authors:  D McMahon; J Jones; A Wiegand; S J Gange; M Kearney; S Palmer; S McNulty; J A Metcalf; E Acosta; C Rehm; J M Coffin; J W Mellors; F Maldarelli
Journal:  Clin Infect Dis       Date:  2010-03-15       Impact factor: 9.079

8.  Productive infection maintains a dynamic steady state of residual viremia in human immunodeficiency virus type 1-infected persons treated with suppressive antiretroviral therapy for five years.

Authors:  Diane V Havlir; Matthew C Strain; Mario Clerici; Caroline Ignacio; Daria Trabattoni; Pasquale Ferrante; Joseph K Wong
Journal:  J Virol       Date:  2003-10       Impact factor: 5.103

9.  Rapid and durable antiretroviral effect of the HIV-1 Integrase inhibitor raltegravir as part of combination therapy in treatment-naive patients with HIV-1 infection: results of a 48-week controlled study.

Authors:  Martin Markowitz; Bach-Yen Nguyen; Eduardo Gotuzzo; Fernando Mendo; Winai Ratanasuwan; Colin Kovacs; Guillermo Prada; Javier O Morales-Ramirez; Clyde S Crumpacker; Robin D Isaacs; Lucinda R Gilde; Hong Wan; Michael D Miller; Larissa A Wenning; Hedy Teppler
Journal:  J Acquir Immune Defic Syndr       Date:  2007-10-01       Impact factor: 3.731

10.  Treatment intensification does not reduce residual HIV-1 viremia in patients on highly active antiretroviral therapy.

Authors:  J B Dinoso; S Y Kim; A M Wiegand; S E Palmer; S J Gange; L Cranmer; A O'Shea; M Callender; A Spivak; T Brennan; M F Kearney; M A Proschan; J M Mican; C A Rehm; J M Coffin; J W Mellors; R F Siliciano; F Maldarelli
Journal:  Proc Natl Acad Sci U S A       Date:  2009-05-22       Impact factor: 11.205

View more
  16 in total

1.  Latent HIV-1 can be reactivated by cellular superinfection in a Tat-dependent manner, which can lead to the emergence of multidrug-resistant recombinant viruses.

Authors:  Daniel A Donahue; Sophie M Bastarache; Richard D Sloan; Mark A Wainberg
Journal:  J Virol       Date:  2013-06-26       Impact factor: 5.103

2.  Single-copy quantification of HIV-1 in clinical samples.

Authors:  Ann Wiegand; Frank Maldarelli
Journal:  Methods Mol Biol       Date:  2014

Review 3.  Eliminating the HIV reservoir.

Authors:  Alain Lafeuillade
Journal:  Curr HIV/AIDS Rep       Date:  2012-06       Impact factor: 5.071

4.  Quantitative analysis of viral persistence and transient viral load rebound from HIV clinical data.

Authors:  Rutao Luo; Michael J Piovoso; Ryan Zurakowski
Journal:  Conf Proc IEEE Eng Med Biol Soc       Date:  2011

5.  Therapeutic vaccination expands and improves the function of the HIV-specific memory T-cell repertoire.

Authors:  Joseph P Casazza; Kathryn A Bowman; Selorm Adzaku; Emily C Smith; Mary E Enama; Robert T Bailer; David A Price; Emma Gostick; Ingelise J Gordon; David R Ambrozak; Martha C Nason; Mario Roederer; Charla A Andrews; Frank M Maldarelli; Ann Wiegand; Mary F Kearney; Deborah Persaud; Carrie Ziemniak; Raphael Gottardo; Julie E Ledgerwood; Barney S Graham; Richard A Koup
Journal:  J Infect Dis       Date:  2013-03-12       Impact factor: 5.226

6.  HIV pathogenesis: dynamics and genetics of viral populations and infected cells.

Authors:  John Coffin; Ronald Swanstrom
Journal:  Cold Spring Harb Perspect Med       Date:  2013-01-01       Impact factor: 6.915

7.  Experiment Design for Early Molecular Events in HIV Infection.

Authors:  Aditya Jagarapu; LaMont Cannon; Ryan Zurakowski
Journal:  Proc Am Control Conf       Date:  2017-07-03

Review 8.  The role of HIV integration in viral persistence: no more whistling past the proviral graveyard.

Authors:  Frank Maldarelli
Journal:  J Clin Invest       Date:  2016-02-01       Impact factor: 14.808

9.  Generation of HIV latency in humanized BLT mice.

Authors:  Paul W Denton; Rikke Olesen; Shailesh K Choudhary; Nancy M Archin; Angela Wahl; Michael D Swanson; Morgan Chateau; Tomonori Nochi; John F Krisko; Rae Ann Spagnuolo; David M Margolis; J Victor Garcia
Journal:  J Virol       Date:  2011-10-19       Impact factor: 5.103

10.  Modelling HIV-1 2-LTR dynamics following raltegravir intensification.

Authors:  Rutao Luo; E Fabian Cardozo; Michael J Piovoso; Hulin Wu; Maria J Buzon; Javier Martinez-Picado; Ryan Zurakowski
Journal:  J R Soc Interface       Date:  2013-05-08       Impact factor: 4.118

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.